Drug intelligence / Profile preview

levallorphan

Development stage
Discontinued
Lead developer
Roche
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous, Intramuscular, Oral
01

Overview

Levallorphan is a synthetic opioid modulator of the morphinan family that acts as both an opioid antagonist and partial agonist. It primarily functions as a competitive antagonist at the mu-opioid receptor (MOR), reversing or preventing effects such as respiratory depression, sedation, and hypotension induced by opioids like morphine. Unlike pure antagonists such as naloxone, levallorphan also exhibits agonist activity at the kappa-opioid receptor (KOR), which can provide mild analgesia but may cause psychotomimetic side effects at higher doses. Historically, it was used to reverse opioid-induced respiratory depression during anesthesia and in cases of narcotic overdose. It was also combined with other opioids (notably pethidine) to reduce their side effects in obstetrics. Its use has declined due to the availability of newer agents like naloxone[1][2][4][5].

Brand names
LorfanNaloxifanNaloxiphan
Other names
levallorphan tartrate
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)CHRNA2 (nAChR α2)

Beyond the preview

Go deeper on levallorphan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on levallorphan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call